β干扰素和γ干扰素协同抑制严重急性呼吸综合征相关冠状病毒（SARS-CoV）的复制。
Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
作者信息
Sainz Bruno, Mossel Eric C, Peters C J, Garry Robert F
机构信息
Department of Microbiology and Immunology, Program in Molecular Pathogenesis and Immunity, Tulane University Health Sciences Center, New Orleans, LA 70112, USA.
出版信息
Virology. 2004 Nov 10;329(1):11-7. doi: 10.1016/j.virol.2004.08.011.
Abstract
Recent studies have shown that interferon-gamma (IFN-gamma) synergizes with IFN-alpha/beta to inhibit the replication of both RNA and DNA viruses. We investigated the effects of IFNs on the replication of two strains of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). While treatment of Vero E6 cells with 100 U/ml of either IFN-beta or IFN-gamma marginally reduced viral replication, treatment with both IFN-beta and IFN-gamma inhibited SARS-CoV plaque formation by 30-fold and replication by 3000-fold at 24 h and by > 1 x 10(5)-fold at 48 and 72 h post-infection. These studies suggest that combination IFN treatment warrants further investigation as a treatment for SARS.
摘要
近期研究表明，γ干扰素（IFN-γ）可与α/β干扰素协同作用，抑制RNA和DNA病毒的复制。我们研究了干扰素对两株严重急性呼吸综合征相关冠状病毒（SARS-CoV）复制的影响。用100 U/ml的β干扰素或γ干扰素处理Vero E6细胞时，病毒复制仅略有减少，而同时用β干扰素和γ干扰素处理时，在感染后24小时，SARS-CoV蚀斑形成受到30倍抑制，病毒复制受到3000倍抑制；在48小时和72小时，病毒复制受到超过1×10⁵倍抑制。这些研究表明，联合使用干扰素治疗作为SARS的一种治疗方法值得进一步研究。
相似文献
1
Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
Virology. 2004 Nov 10;329(1):11-7. doi: 10.1016/j.virol.2004.08.011.
2
The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced proteins.
Intervirology. 2007;50(2):156-60. doi: 10.1159/000098242. Epub 2006 Dec 22.
3
Interferon-beta 1a and SARS coronavirus replication.
Emerg Infect Dis. 2004 Feb;10(2):317-9. doi: 10.3201/eid1002.030482.
4
Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.
Antivir Ther. 2004 Dec;9(6):1003-11.
5
In vitro inhibition of SARS virus replication by human interferons.
Scand J Infect Dis. 2004;36(11-12):829-31. doi: 10.1080/00365540410021144.
6
Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
mBio. 2020 Sep 10;11(5):e01928-20. doi: 10.1128/mBio.01928-20.
7
Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines.
Biochem Biophys Res Commun. 2005 Jan 28;326(4):905-8. doi: 10.1016/j.bbrc.2004.11.128.
8
The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein.
J Clin Virol. 2004 Jul;30(3):211-3. doi: 10.1016/j.jcv.2003.11.013.
9
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV.
J Virol. 2020 Nov 9;94(23). doi: 10.1128/JVI.01410-20.
10
Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice.
Antivir Chem Chemother. 2006;17(5):275-84. doi: 10.1177/095632020601700505.
引用本文的文献
1
Identification of key signaling pathways and novel computational drug target for oral cancer, metabolic disorders and periodontal disease.
J Genet Eng Biotechnol. 2024 Dec;22(4):100431. doi: 10.1016/j.jgeb.2024.100431. Epub 2024 Oct 22.
2
and Combination Modulates IFN-γ, IL-10, and SOCS3 in Rotavirus-Infected Cells.
Int J Mol Sci. 2024 May 18;25(10):5514. doi: 10.3390/ijms25105514.
3
Harnessing the power of IFN for therapeutic approaches to COVID-19.
J Virol. 2024 May 14;98(5):e0120423. doi: 10.1128/jvi.01204-23. Epub 2024 Apr 23.
4
Interferon- as a Potential Inhibitor of SARS-CoV-2 ORF6 Accessory Protein.
Int J Mol Sci. 2024 Feb 10;25(4):2155. doi: 10.3390/ijms25042155.
5
Immune-Stimulating Potential of LM1019 in RAW 264.7 Cells and Immunosuppressed Mice Induced by Cyclophosphamide.
Microorganisms. 2023 Sep 13;11(9):2312. doi: 10.3390/microorganisms11092312.
6
Expression of IFN-Gamma is significantly reduced during severity of covid-19 infection in hospitalized patients.
PLoS One. 2023 Sep 27;18(9):e0291332. doi: 10.1371/journal.pone.0291332. eCollection 2023.
7
A co-formulation of interferons alpha2b and gamma distinctively targets cell cycle in the glioblastoma-derived cell line U-87MG.
BMC Cancer. 2023 Aug 29;23(1):806. doi: 10.1186/s12885-023-11330-2.
8
Identification of common molecular signatures of SARS-CoV-2 infection and its influence on acute kidney injury and chronic kidney disease.
Front Immunol. 2023 Mar 21;14:961642. doi: 10.3389/fimmu.2023.961642. eCollection 2023.
9
Multimodal characterization of antigen-specific CD8 T cells across SARS-CoV-2 vaccination and infection.
bioRxiv. 2023 Jan 24:2023.01.24.525203. doi: 10.1101/2023.01.24.525203.
10
Systematic approach to identify therapeutic targets and functional pathways for the cervical cancer.
J Genet Eng Biotechnol. 2023 Feb 1;21(1):10. doi: 10.1186/s43141-023-00469-x.
本文引用的文献
1
The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein.
J Clin Virol. 2004 Jul;30(3):211-3. doi: 10.1016/j.jcv.2003.11.013.
2
Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha.
J Infect Dis. 2004 Apr 1;189(7):1164-7. doi: 10.1086/382597. Epub 2004 Mar 12.
3
Interferon-beta 1a and SARS coronavirus replication.
Emerg Infect Dis. 2004 Feb;10(2):317-9. doi: 10.3201/eid1002.030482.
4
SARS-related virus predating SARS outbreak, Hong Kong.
Emerg Infect Dis. 2004 Feb;10(2):176-8. doi: 10.3201/eid1002.030533.
5
Current concepts in SARS treatment.
J Infect Chemother. 2004 Feb;10(1):1-7. doi: 10.1007/s10156-003-0296-9.
6
Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus.
J Virol. 2004 Mar;78(6):3162-9. doi: 10.1128/jvi.78.6.3162-3169.2004.
7
Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.
Nat Med. 2004 Mar;10(3):290-3. doi: 10.1038/nm1001. Epub 2004 Feb 22.
8
Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study.
JAMA. 2003 Dec 24;290(24):3222-8. doi: 10.1001/jama.290.24.3222.
9
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.
Nature. 2003 Nov 27;426(6965):450-4. doi: 10.1038/nature02145.
10
Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China.
Science. 2003 Oct 10;302(5643):276-8. doi: 10.1126/science.1087139. Epub 2003 Sep 4.
Zotero 插件